The structure of EXTL3 helps to explain the different roles of bi-domain exostosins in heparan sulfate synthesis
View / Open Files
Authors
Wilson, louis
Echevarria-poza, alberto
Dendooven, Tom
krogh, Kris
logan, Derek
mani, Katrin
Publication Date
2022-06-08Journal Title
Nature Communications
ISSN
2041-1723
Publisher
Nature Research
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Dupree, P., Wilson, l., Echevarria-poza, a., Dendooven, T., Hardwick, S., Tryfona, T., krogh, K., et al. (2022). The structure of EXTL3 helps to explain the different roles of bi-domain exostosins in heparan sulfate synthesis. Nature Communications https://doi.org/10.1038/s41467-022-31048-2
Abstract
Heparan sulfate is a highly modified O-linked glycan that performs diverse physiological roles
in animal tissues. Though quickly modified, it is initially synthesised as a polysaccharide of
alternating β-D-glucuronosyl and N-acetyl-α-D-glucosaminyl residues by exostosins. These
enzymes generally possess two glycosyltransferase domains (GT47 and GT64)—each thought
to add one type of monosaccharide unit to the backbone. Although previous structures of
murine exostosin-like 2 (EXTL2) provide insight into the GT64 domain, the rest of the bidomain
architecture is yet to be characterised; hence, how the two domains co-operate is
unknown. Here, we report the structure of human exostosin-like 3 (EXTL3) in apo and UDPbound
forms. We explain the ineffectiveness of EXTL3’s GT47 domain to transfer β-Dglucuronosyl
units, and we observe that, in general, the bi-domain architecture would preclude
a processive mechanism of backbone extension. We therefore propose that heparan sulfate
backbone polymerisation occurs by a simple dissociative mechanism.
Sponsorship
This work was funded by grants from the University of Cambridge, BBSRC OpenPlant (BB/L014130/1,
P.D.), the Swedish Research Council (2014-03402, K.M.; 2016-04855, D.T.L.), Cancerfonden
(21 1426 Pj 01 H, K.M.), and the Wellcome Trust (200873/Z/16/Z, B.F.L.). L.F.L.W. was
supported by the University of Cambridge. T.D. was supported by an AstraZeneca studentship.
Funder references
Biotechnology and Biological Sciences Research Council (BB/L014130/1)
Wellcome Trust (200873/Z/16/Z)
Identifiers
External DOI: https://doi.org/10.1038/s41467-022-31048-2
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338352
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk